Impact of generic substitution on pharmaceutical prices and expenditures in OECD countries

Journal of Pharmaceutical Finance, Economics and Policy

Volumn 15, Issue 1, 2006, Pages 41-63

  Buzzelli, Carlo ^a   Kangasharju, Aki ^b   Linnosmaa, Ismo ^a   Valtonen, Hannu ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b Valtion taloudellinen tutkimuskeskus Finland   (Finland)

Author keywords

Competition; Pharmaceuticals; Prices

Indexed keywords

GENERIC DRUG;

DRUG COST; DRUG INDUSTRY; DRUG MARKETING; PHARMACY; POLICY; PRIORITY JOURNAL; REVIEW; THEORETICAL MODEL;

EID: 33747109117     PISSN: 15385698     EISSN: 15385396     Source Type: Journal    
DOI: 10.1300/J371v15n01_06     Document Type: Review

References (17)

1. Aalto-Setälä, V. 2004. Kilpailun hintoja laskeva vaikutus- tapaus lääkevaihto, Talous ja yhteiskunta 4/2004: 41-46.
2. Bertrand, M., E. Duflo, and S. Mullainathan. 2004. How much should we trust on difference-in-differences estimates? Quarterly Journal of Economics 199: 249-275.
3. Ellison, G., and S.F. Ellison. 2000. Strategic entry deterrence and the behavior of pharmaceutical incumbents prior to patent expiration. Working Paper, Department of Economics, MIT.
4. Ellison, S.F., I. Cockburn, Z. Griliches, and J. Hausman. 1997. Characteristics of demand for pharmaceutical products: an examination of four cephalosporins. RAND Journal of Economics 28: 426-446.
5. Ferrandiz, J.M. 1999. The impact of generic goods in the pharmaceutical industry. Health Economics 8: 599-612.
6. Frank, R.G., and D.S. Salkever. 1991, Pricing, patent loss, and the market for pharmaceuticals. National Bureau of Economic Research, Working Paper # 3803.
7. Frank, R.G., and D.S. Salkever. 1992. Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal 59: 165-179.
8. Frank, R.G., and D.S. Salkever. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6: 75-90.
9. Grabowski, H., and J. Vernon. 1992. Brand loyalty, entry and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35: 331-350.
10. Henriksson, F., C. Hiortsberg, and C. Rehnberg. 1999. Pharmaceutical expenditure in Sweden. Health Policy 47: 125-144.
11. LaLonde, R. 1986. Evaluating the econometric evaluations of training programs with experimental data. American Economic Review 76: 604-620.
12. Lexchin, J. 2004. The effect of generic competition on the price of the brand-name drugs. Health Policy 68: 47-54.
13. O'Brien, B. 1989. The effect of patient charges on the utilisation of prescription medicines. Journal of Health Economics 8: 109-32
14. Satterthwaite, M., and D. Dranove. (2000) Industrial organization of health care markets, in Culyer, Anthony, and Joseph Newhouse, eds. 2000. The Handbook of Health Economics. Amsterdam: Elsevier Science.
15. Scott Morton, F.M. 1999. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30: 421-440.
16. Scott Morton, F.M. 2000. Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. International Journal of Industrial Organization 18: 1085-1104.
17. Tirole, J. 1988. Theory of Industrial Organization. Cambridge, Massachusetts: MIT Press.